Opendata, web and dolomites

PORTAL SIGNED

Personalized oncology for refractory and relapsed lymphoma using humanized patient derived othotopic xenografts (ImmunePDOX)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PORTAL project word cloud

Explore the words cloud of the PORTAL project. It provides you a very rough idea of what is the project "PORTAL" about.

reintegrated    farre    therapeutic    improvement    engagement    refractory    patient    public    brazil    12    europdx    gender    2020    portal    position    lymphoma    humanized    re    alberto    board    htlv    innovative    hematology    xenograft    clinical    models    transfer    original    ana    ico    policy    sureda    option    privileged    resistance    spin    cancers    supervised    catalan    contributed    educational    combined    overcoming    lymphomas    fiocruz    always    xenopat    pharmaceuticals    programmed    solid    career    empiric    treatment    preclinical    paradigm    she    director    off    reflects    relevantly    acquired    training    personalized    priorities    biomedical    barcelona    leader    cruz    of    maturity    bellvitge    incorporate    strategy    infection    service    researcher    qualitative    independent    multidisciplinary    head    line    scientific    initiating    therapy    group    relapsed    spain    hematological    idibell    orthotopic    mechanisms    oswaldo    villanueva    foundation    lourdes    chemotherapy    worked    oncology    interventions    proof    besides    dr    remained   

Project "PORTAL" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE 

Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908
website: www.idibell.cat

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE ES (L'HOSPITALET DE LLOBREGAT) coordinator 170˙121.00

Map

 Project objective

This proposal is a “PORTAL” to re-incorporate Dr. Lourdes Farre from the Oswaldo Cruz Foundation (FIOCRUZ) in Brazil to Europe at the Catalan Institute of Oncology (ICO), a part of the Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. She will be supervised by Dr. Alberto Villanueva, leader of the Resistance, Chemotherapy and Orthotopic Xenograft Models Group and Director Board of the EuroPDX (www.europdx.eu) in collaboration with Dr. Ana Sureda, Head of the Hematology Department (ICO). Dr. Farre worked at FIOCRUZ for 12 years where she relevantly contributed in lymphoma research and acquired maturity as an independent researcher. Dr. Farre will contribute to ICO/IDIBELL initiating a new research line in resistance in hematological cancers and transfer her knowledge in HTLV-1 infection. She will also contribute to the ICO Hematology Service with a personalized oncology strategy for clinical oncology practice. Knowledge and preclinical models could be transfer to the IDIBELL`s spin-off Xenopat and Pharmaceuticals. She will have access to a solid multidisciplinary training program that will provide qualitative improvement on her career and a privileged position to be reintegrated in a long term research position in Europe. She has always combined scientific activity with educational interventions. Besides scientific dissemination, she programmed public engagement activities. This proposal is a proof-of-concept of personalized oncology for refractory/relapsed lymphoma and aims to study the mechanisms involved in response to therapy using preclinical humanized orthotopic models. Relapsed/refractory lymphomas represent a major treatment challenge and general treatment paradigm has remained empiric. Defining the best therapeutic option for each patient and overcoming such resistance is a priority. Humanized and orthotopic approach is original and innovative. PORTAL reflects the policy priorities of the Europe 2020 strategy and considers gender issues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PORTAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PORTAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

IRF4 Degradation (2019)

Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells

Read More  

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

LEVERAGE mRNA (2019)

Laboratory Evolution of Virus-likE pRotein cAGes for Eukaryotic mRNA delivery

Read More